Advertisement
The new Pharmacor report entitled Chronic Pain finds that, followingrecovery from the withdrawals in 2004 and 2005 of two COX-2 inhibitors, thechronic pain market will regain momentum over the next decade, with 5 to 6%annual growth in total sales in the United States, France, Germany, Italy,Spain, United Kingdom and Japan.
Advertisement
"In contrast to older established drugs like amitriptyline, new agentssuch as Lyrica and Cymbalta have the safety and efficacy data from large-scaleclinical trials that will allow them to compete in this market," said KateHohenberg, director at Decision Resources. "Both of these drugs will achieveblockbuster status in the chronic pain drug market by 2011 and sales of Lyricawill exceed $2 billion by 2016."
The chronic pain drug market in Japan will be particularly robust from2011 to 2016 as drugs that include Cymbalta, Lyrica and Endo's Lidoderm reachthat market. Also driving growth in Japan will be Pfizer's Celebrex whichreached the Japanese market in 2007. The report also finds that the continueduse of opioid analgesics for chronic, non-cancer pain and the introduction ofmore-tolerable, safer opioid formulations in the next five years will driveopioid analgesic sales for chronic pain to more than $6 billion by 2016 in theUnited States, France, Germany, Italy, Spain, United Kingdom and Japan.
About Chronic Pain
Key chronic pain populations, which account for approximately 80% of thedrug market for chronic pain therapies and are covered in the report, includearthritic pain, chronic low back pain, fibromyalgia, diabetic neuropathicpain, postherpetic neuralgia, HIV-related neuropathic pain, chronic headache(including transformed migraine) and cancer pain. Sales of drugs to treatthese and other, less clearly defined chronic pain conditions exceeded $14billion in 2006 in the world's major pharmaceutical markets.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in marketresearch publications, advisory services, and consulting designed to helpclients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]
SOURCE Decision Resources
